U.S.-based biotech BridGene Biosciences Inc. has completed a Series B financing round, raising USD 38.5 million. The round was backed by China-based funds, including Beijing’s Lapam Capital, Hong Kong’s Junson Capital, and Xiamen’s Dyee Capital.
Funding Use
Proceeds will support the development of BridGene’s proprietary chemoproteomic platform IMTAC, including clinical trials for its lead pipeline candidate—a preclinical covalent TEAD inhibitor targeting the Hippo signaling pathway.
Technology Profile
BridGene’s IMTAC platform screens small-molecule drugs against the whole proteome or live targets in live cells, enabling the discovery of drug candidates for previously “undruggable” targets.-Fineline Info & Tech
